<DOC>
	<DOCNO>NCT00730470</DOCNO>
	<brief_summary>This Phase 1 clinical study investigate safety , pharmacokinetics , pharmacodynamics U3-1287 ( AMG 888 ) , fully human monoclonal antibody target HER3 receptor , patient advance solid tumor . Eligible patient disease refractory resistant standard treatment standard therapy exists . The study conduct two part ; dose escalation ( Part 1 ) dose expansion ( Part 2 ) . The hypothesis study U3-1287 ( AMG888 ) safe well tolerated patient advance solid tumor show initial evidence anti-tumor activity .</brief_summary>
	<brief_title>Phase I Study U3P1287/01 , Including Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Key Pathologically cytologically document advanced solid tumor refractory standard treatment , standard therapy available , patient refuse standard therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Men woman least 18 year age Adequate hematologic , cardiac , renal , hepatic , metabolic , coagulation function Key Presence untreated symptomatic brain metastasis . Presence ascites pleural effusion require chronic medical intervention . Uncontrolled hypertension Concurrent previous ( within 1 week study day 1 ) anticoagulation therapy , except lowdose warfarin ( ≤ 2 mg/day ) low dose , low molecular weight heparin prophylaxis central venous catheter thrombosis . Recent major surgical procedure yet recover major surgery Recent participation clinical drug trial . Participation investigational procedure . Unresolved toxicity prior anticancer therapy Patient pregnant ( e.g . positive human choriogonadotropin [ HCG ] test ) nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Human Epidermal Growth Factor Receptor 3</keyword>
	<keyword>HER3</keyword>
	<keyword>Heregulin</keyword>
	<keyword>erb B3</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase I Clinical Study</keyword>
</DOC>